The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials

• Published in: Diabetes, metabolic syndrome and obesity Vol. 16; pp. 575 - 595
• Main Authors: Aldawsari, Malikah, Almadani, Fatima A, Almuhammadi, Nujud, Algabsani, Sarah, Alamro, Yara, Aldhwayan, Madhawi
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2023; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Adults; Appetite; Bias; Chronic diseases; Clinical trials; Collaboration; Data collection; Diabetes; Diet; Drug dosages; Drug therapy; Epidemiology; FDA approval; gastric emptying; Gastrointestinal surgery; glp-1 analogues; Glucagon; Hormones; Intervention; Liraglutide; Lorcaserin; Medical research; Medicine, Experimental; Obesity; palatability; Peptides; Preferences; Review; satiety; semaglutide; Systematic review; Weight control; satiety; GLP-1 analogues; Semaglutide; appetite; gastric emptying; Liraglutide; palatability
• ISSN: 1178-7007; 1178-7007
• DOI: 10.2147/DMSO.S387116

Obesity is an epidemiological issue that negatively affects public health and has led to a high global burden on the healthcare system. Several approaches to control and overcome the obesity crisis have been established. However, Nobel discoverers found that glucagon-like peptide-1 analogues (GLP-1 analogues) positively regulate appetite and food intake, eventually leading to weight loss. The present systematic review aims to summarize the currently available evidence of the impact of GLP-1 analogues on appetite, gastric emptying, taste sensitivity, and food preferences among adults with obesity without other chronic diseases. A systematic literature search was conducted from October 2021 to December 2021 from three electronic databases (PubMed, Scopus, and ScienceDirect), including only randomized clinical trials (RCTs). Studies were based on the use of GLP-1 analogues, of any dosage and duration among adults with obesity without other medical diseases; studies measured appetite, gastric emptying, food preferences, and taste as a primary or secondary outcome. The risk of publication bias in each study was assessed independently using the updated Cochrane risk-of-bias tool (RoB2). Twelve studies met the inclusion criteria with a total sample size of 445 participants. All the included studies measured at least one or more of the primary outcomes. The promising effect was evidenced by most studies showing appetite suppression, delayed gastric emptying, and changes in taste and food preferences. GLP-1 analogues are effective obesity management therapy that could decrease food intake and eventually reduce weight by suppressing appetite, reducing hunger, decreasing gastric emptying, and altering food preferences and taste. However, high-quality, long-term, large sample size studies are crucial to examine the efficacy and effective dose of GLP-1 analogues intervention.